Concepedia

Publication | Closed Access

Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma

36

Citations

14

References

2014

Year

Abstract

Sorafenib may be effective and well tolerated, even in patients with advanced HCC who are aged 80 years and older, as well as those aged less than 80 years.

References

YearCitations

Page 1